These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 25959151)

  • 1. Neuraminidase inhibitor therapy in a military population.
    Fairchok MP; Chen WJ; Arnold JC; Schofield C; Danaher PJ; McDonough EA; Ottolini M; Mor D; Ridore M; Burgess TH; Millar EV
    J Clin Virol; 2015 Jun; 67():17-22. PubMed ID: 25959151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of neuraminidase inhibitors in primary health care during pandemic and seasonal influenza between 2009 and 2013.
    Blanchon T; Geffrier F; Turbelin C; Daviaud I; Laouénan C; Duval X; Lambert B; Hanslik T; Mosnier A; Leport C
    Antivir Ther; 2015; 20(7):753-61. PubMed ID: 25687219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of neuraminidase inhibitors in preventing hospitalization during the H1N1 influenza pandemic in British Columbia, Canada.
    Marra F; Chong M; Henry B; Patrick DM; Kendall P
    J Antimicrob Chemother; 2014 May; 69(5):1397-406. PubMed ID: 24346762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prescribing of neuraminidase inhibitors for influenza in UK primary care since the 2009 pandemic.
    Hardelid P; Rait G; Gilbert R; Petersen I
    Epidemiol Infect; 2016 Mar; 144(4):772-6. PubMed ID: 26364671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and effectiveness of neuraminidase inhibitors in situations of pandemic and/or novel/variant influenza: a systematic review of the literature, 2009-15.
    Boikos C; Caya C; Doll MK; Kraicer-Melamed H; Dolph M; Delisle G; Winters N; Gore G; Quach C
    J Antimicrob Chemother; 2017 Jun; 72(6):1556-1573. PubMed ID: 28204554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison between virus shedding and fever duration after treating children with pandemic A H1N1/09 and children with A H3N2 with a neuraminidase inhibitor.
    Sugaya N; Sakai-Tagawa Y; Bamba M; Yasuhara R; Yamazaki M; Kawakami C; Yamaguchi Y; Ide Y; Ichikawa M; Mitamura K; Kawaoka Y
    Antivir Ther; 2015; 20(1):49-55. PubMed ID: 24832015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid influenza diagnostic test use and antiviral prescriptions in outpatient settings pre- and post-2009 H1N1 pandemic.
    Williams LO; Kupka NJ; Schmaltz SP; Barrett S; Uyeki TM; Jernigan DB
    J Clin Virol; 2014 May; 60(1):27-33. PubMed ID: 24630481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Global assessment of resistance to neuraminidase inhibitors, 2008-2011: the Influenza Resistance Information Study (IRIS).
    Whitley RJ; Boucher CA; Lina B; Nguyen-Van-Tam JS; Osterhaus A; Schutten M; Monto AS
    Clin Infect Dis; 2013 May; 56(9):1197-205. PubMed ID: 23307766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and safety of neuraminidase inhibitors in reducing influenza complications: a meta-analysis of randomized controlled trials.
    Falagas ME; Koletsi PK; Vouloumanou EK; Rafailidis PI; Kapaskelis AM; Rello J
    J Antimicrob Chemother; 2010 Jul; 65(7):1330-46. PubMed ID: 20488984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuraminidase Inhibitors and Hospital Mortality in British Patients with H1N1 Influenza A: A Re-Analysis of Observational Data.
    Wolkewitz M; Schumacher M
    PLoS One; 2016; 11(9):e0160430. PubMed ID: 27583403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical effectiveness of neuraminidase inhibitors--oseltamivir, zanamivir, laninamivir, and peramivir--for treatment of influenza A(H3N2) and A(H1N1)pdm09 infection: an observational study in the 2010-2011 influenza season in Japan.
    Shobugawa Y; Saito R; Sato I; Kawashima T; Dapat C; Dapat IC; Kondo H; Suzuki Y; Saito K; Suzuki H
    J Infect Chemother; 2012 Dec; 18(6):858-64. PubMed ID: 22644080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial.
    Fry AM; Goswami D; Nahar K; Sharmin AT; Rahman M; Gubareva L; Azim T; Bresee J; Luby SP; Brooks WA
    Lancet Infect Dis; 2014 Feb; 14(2):109-18. PubMed ID: 24268590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes and Susceptibility to Neuraminidase Inhibitors in Individuals Infected With Different Influenza B Lineages: The Influenza Resistance Information Study.
    van der Vries E; Ip DK; Cowling BJ; Zhang JD; Tong X; Wojtowicz K; Schutten M; Boucher CA
    J Infect Dis; 2016 Jan; 213(2):183-90. PubMed ID: 26160744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum strain-specific or cross-reactive neuraminidase inhibiting antibodies against pandemic А/California/07/2009(H1N1) influenza in healthy volunteers.
    Desheva YA; Smolonogina TA; Donina SA; Rudenko LG
    BMC Res Notes; 2015 Apr; 8():136. PubMed ID: 25889924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro neuraminidase inhibitory activity of four neuraminidase inhibitors against influenza virus isolates in the 2011-2012 season in Japan.
    Ikematsu H; Kawai N; Iwaki N; Kashiwagi S
    J Infect Chemother; 2014 Feb; 20(2):77-80. PubMed ID: 24560563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuraminidase inhibitors: progress in the management of influenza.
    Woodhead M; Lavanchy D; Johnston S; Colman P; Fleming D
    Int J Clin Pract; 2000 Nov; 54(9):604-10. PubMed ID: 11220989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro neuraminidase inhibitory concentration (IC
    Ikematsu H; Kawai N; Iwaki N; Kashiwagi S
    J Infect Chemother; 2017 Sep; 23(9):609-614. PubMed ID: 28655503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influenza Antiviral Expenditures and Outpatient Prescriptions in the United States, 2003-2012.
    Suda KJ; Hunkler RJ; Matusiak LM; Schumock GT
    Pharmacotherapy; 2015 Nov; 35(11):991-7. PubMed ID: 26598091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors.
    Hatakeyama S; Sugaya N; Ito M; Yamazaki M; Ichikawa M; Kimura K; Kiso M; Shimizu H; Kawakami C; Koike K; Mitamura K; Kawaoka Y
    JAMA; 2007 Apr; 297(13):1435-42. PubMed ID: 17405969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials.
    Cooper NJ; Sutton AJ; Abrams KR; Wailoo A; Turner D; Nicholson KG
    BMJ; 2003 Jun; 326(7401):1235. PubMed ID: 12791735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.